The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for risdiplam (Evrysdi), the first treatment that can be given ...
NEW YORK, April 3, 2012 /PRNewswire via COMTEX/ -- The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM's Multi-Analyte Profiling ...
Organizations plan to develop panel of biomarker assays for use in clinical trials of SMA therapeutic candidates. The Spinal Muscular Atrophy (SMA) Foundation and Rules-Based Medicine report reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results